Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Trovagene to Attend the 28th Annual Piper Jaffray Healthcare Conference

Posted on: 22 Nov 16

SAN DIEGO, Calif., Nov. 22, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, is scheduled to attend the 28th Annual Piper Jaffray Healthcare Conference, November 29-30, 2016, at the Lotte New York Palace in New York City. 

Bill Welch, Chief Executive Officer of Trovagene, will be attending the conference and participating in a thirty-minute "fireside chat" with a Piper Jaffray equity analyst on Wednesday, November 30.  No formal presentation is being made.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary Precision Cancer Monitoring® (PCM) technology for the detection and monitoring of circulating tumor DNA (ctDNA) in urine. The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's PCM technology is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Trovagene Contacts


Beth Anderson

VP, Finance & Administration


Vicki Kelemen

Sr. Director, Marketing Communications




For more information:

Editor's Details

Mike Wood

Last updated on: 22/11/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.